Aptose Biosciences Inc

NASDAQ:APTOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

View on Canadian Exchange

Aptose Biosciences Inc. is a clinical-stage biotechnology company engaged in developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Contact Information

Headquarters

251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3

Phone

647-479-9828

Fax

416-798-2200

Executives

Chairman of the Board, President, Chief Executive Officer

William Rice

Chief Financial Officer, Senior Vice President, Company Secretary, Chief Business Officer

Fletcher Payne

Senior Vice President, Chief Medical Officer

Rafael Bejar

Lead Independent Director

Denis Burger

Independent Director

Carol Ashe